Research
Immune infiltrate predicts response to αPD1/αCTLA4 but not αPD1 and distinguishes programs of primary resistance in metastatic melanoma
Science · By Amy Y. Huang, Kelly P. Burke, Marc C. Glettig, Ryan Porter, Peter Fatouros, Jonathan M. Li, Lynn Meiger, Valeria Rosado, Shuyun Xu, Jiekun Yang, Emily Robitschek, Natalie Vokes, Cora Ricker, Giuseppe Tarantino, Jiajia Chen, Tyler J. Aprati, Yiwen He, Cassia Wang, Doris Fu, Li-Lun Ho, Kyriakitsa Galani, Gordon J. Freeman, Elizabeth I. Buchbinder, F. Stephen Hodi, Christine G. Lian, Manolis Kellis, Genevieve M. Boland, Arlene H. Sharpe & David Liu ·
The Brief
- A Science Advances study finds that the immune infiltrate in metastatic melanoma predicts response to combined anti-PD1 and anti-CTLA4 checkpoint blockade.
- The immune infiltrate does not predict response to anti-PD1 alone.
- The study distinguishes programs of primary resistance in metastatic melanoma.
Why it matters
It suggests that tumour immune infiltrate may help identify which metastatic melanoma patients are likely to respond to combined checkpoint blockade, a question that bears on treatment choice.
Who’s affected
- oncologists and melanoma researchers
- cancer immunology researchers
- #melanoma
- #immunotherapy
- #checkpoint blockade
- #immune infiltrate
- #cancer biomarkers
Science Advances, Volume 12, Issue 47 , November 2026.